In:
PLOS ONE, Public Library of Science (PLoS), Vol. 16, No. 2 ( 2021-2-25), p. e0246958-
Abstract:
Since 2010, nationwide networks of reference centers for sarcomas (RREPS/NETSARC/RESOS) collected and prospectively reviewed all cases of sarcomas and connective tumors of intermediate malignancy (TIM) in France. Methods The nationwide incidence of sarcoma or TIM (2013–2016) was measured using the 2013 WHO classification and confirmed by a second independent review by expert pathologists. Simple clinical characteristics, yearly variations and correlation of incidence with published clinical trials are presented and analyzed. Results Over 150 different histological subtypes are reported from the 25172 patients with sarcomas (n = 18712, 74,3%) or TIM (n = 6460, 25.7%), with n = 5838, n = 6153, n = 6654, and n = 6527 yearly cases from 2013 to 2016. Over these 4 years, the yearly incidence of sarcomas and TIM was therefore 70.7 and 24.4 respectively, with a combined incidence of 95.1/10 6 /year, higher than previously reported. GIST, liposarcoma, leiomyosarcomas, undifferentiated sarcomas represented 13%, 13%, 11% and 11% of tumors. Only GIST, as a single entity had a yearly incidence above 10/10 6 /year. There were respectively 30, 64 and 66 different histological subtypes of sarcomas or TIM with an incidence ranging from 10 to 1/10 6 , 1–0.1/10 6 , or 〈 0.1/10 6 /year respectively. The 2 latter incidence groups represented 21% of the patients with 130 histotypes. Published phase III and phase II clinical trials (p 〈 10 −6 ) are significantly higher with sarcomas subtypes with an incidence above 1/10 6 per. Conclusions This nationwide registry of sarcoma patients, with exhaustive histology review by sarcoma experts, shows that the incidence of sarcoma and TIM is higher than reported, and that tumors with a very low incidence (1 〈 10 6 /year) are less likely to be included in clinical trials.
Type of Medium:
Online Resource
ISSN:
1932-6203
DOI:
10.1371/journal.pone.0246958
DOI:
10.1371/journal.pone.0246958.g001
DOI:
10.1371/journal.pone.0246958.t001
DOI:
10.1371/journal.pone.0246958.t002
DOI:
10.1371/journal.pone.0246958.t003
DOI:
10.1371/journal.pone.0246958.t004
DOI:
10.1371/journal.pone.0246958.s001
DOI:
10.1371/journal.pone.0246958.s002
DOI:
10.1371/journal.pone.0246958.s003
DOI:
10.1371/journal.pone.0246958.s004
DOI:
10.1371/journal.pone.0246958.s005
DOI:
10.1371/journal.pone.0246958.s006
DOI:
10.1371/journal.pone.0246958.s007
DOI:
10.1371/journal.pone.0246958.s008
DOI:
10.1371/journal.pone.0246958.s009
DOI:
10.1371/journal.pone.0246958.r001
DOI:
10.1371/journal.pone.0246958.r002
DOI:
10.1371/journal.pone.0246958.r003
DOI:
10.1371/journal.pone.0246958.r004
DOI:
10.1371/journal.pone.0246958.r005
DOI:
10.1371/journal.pone.0246958.r006
DOI:
10.1371/journal.pone.0246958.r007
DOI:
10.1371/journal.pone.0246958.r008
Language:
English
Publisher:
Public Library of Science (PLoS)
Publication Date:
2021
detail.hit.zdb_id:
2267670-3
Bookmarklink